MedPath

Hepatitis Resource Network

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

3

Active:0
Completed:2

Trial Phases

1 Phases

Phase 3:3

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials

Phase 3
3 (100.0%)

HRN 004- Peginterferon a-2a Plus Ribavirin for Chronic Hepatitis C Infection in HIV Infected Persons Who Have Failed to Achieve a Sustained Virologic Response Following Previous Interferon Therapy

Phase 3
Conditions
HIV Infections
Chronic Hepatitis C Infection in HIV Infected Persons
First Posted Date
2005-09-22
Last Posted Date
2005-10-25
Lead Sponsor
Hepatitis Resource Network
Registration Number
NCT00215839
Locations
🇺🇸

Mt. Sinai School of Medicine, New York, New York, United States

PEG-Interferon a-2b + Ribavirin for Treatment of Chronic HRN 005 Hepatitis C Infection in HIV-Infected Persons Not Previously Treated With Interferon

Phase 3
Completed
Conditions
Chronic Hepatitis C Infection in HIV-Infected Persons
HIV Infections
First Posted Date
2005-09-22
Last Posted Date
2005-10-25
Lead Sponsor
Hepatitis Resource Network
Target Recruit Count
300
Registration Number
NCT00215891
Locations
🇺🇸

Johns Hopkins University School of Medicine, Baltimore, Maryland, United States

PEG-Interferon a-2b + Ribavirin for Treatment of Patients With Chronic Hepatitis C Who Have Previously Failed to Achieve a Sustained Virologic Response Following Interferon Alfa or Interferon a-2b + Ribavirin Therapy

Phase 3
Completed
Conditions
Chronic Hepatitis C Virus Infection
First Posted Date
2005-09-22
Last Posted Date
2005-09-22
Lead Sponsor
Hepatitis Resource Network
Target Recruit Count
600
Registration Number
NCT00215865
Locations
🇺🇸

Johns Hopkins Univesity School of Medicine, Baltimore, Maryland, United States

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.